New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023
European Heart Journal - Cardiovascular Pharmacotherapy · 2024
DOI: 10.1093/ehjcvp/pvae013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2024. Verfasst von Juan Tamargo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto De Investigación Sanitaria Gregorio Marañón, 28040 …. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Cardiovascular Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, Wellcome Trust, NHLBI NIH HHS.
Abstract (Originalsprache)
Although cardiovascular diseases (CVDs) are the leading cause of death worldwide, their pharmacotherapy remains suboptimal. Thus, there is a clear unmet need to develop more effective and safer pharmacological strategies. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2023, including the approval of first-in-class drugs that open new avenues for the treatment of atherosclerotic CVD and heart failure (HF). The new indications of drugs already marketed (repurposing) for the treatment of obstructive hypertrophic cardiomyopathy, hypercholesterolaemia, type 2 diabetes, obesity, and HF; the impact of polypharmacy on guideline-directed drug use is highlighted as well as results from negative clinical trials. Finally, we end with a summary of the most important phase 2 and 3 clinical trials assessing the efficacy and safety of cardiovascular drugs under development for the prevention and treatment of CVDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto De Investigación Sanitaria Gregorio Marañón, 28040 Madrid, Spain.
- Institute of Clinical Science, Oslo University, 0318 Oslo, Norway.
- Institute of Clinical Sciences, Karolinska Institute, Danderyd Hospital, 171 77 Stockholm, Sweden.
- Department of Cardiovascular Medicine, University of Bologna-IRCCS AOU S. Orsola, 40138 Bologna, Italy.
- Motusmed Clinic, 25122 Brescia, Italy.
- Department Neurofarba, Section of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.
ORCID-Profile: Juan Tamargo, Claudio Borghi, Elisabetta Cerbai, Patrick Sulzgruber, Alexander Niessner, Dobromir Dobrev
Förderung
- Medical Research Council
- Wellcome Trust
- NHLBI NIH HHS
- EU
- NIH HHS
- National Institutes of Health
Zitieren
APA
Tamargo, J., Agewall, S., Borghi, C., Ceconi, C., Cerbai, E., Dan, G. A., Ferdinandy, P., Grove, E. L., Rocca, B., Magavern, E., Sulzgruber, P., Semb, A. G., Sossalla, S., Niessner, A., Kaski, J. C., & Dobrev, D. (2024). New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae013
Vancouver
Tamargo J, Agewall S, Borghi C, Ceconi C, Cerbai E, Dan GA, et al. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023. European Heart Journal - Cardiovascular Pharmacotherapy. 2024. doi:10.1093/ehjcvp/pvae013
BibTeX
@article{Tamargo2024,
author = {Tamargo, Juan and Agewall, Stefan and Borghi, Claudio and Ceconi, Claudio and Cerbai, Elisabetta and Dan, Gheorghe A and Ferdinandy, Péter and Grove, Erik Lerkevang and Rocca, Bianca and Magavern, Emma and Sulzgruber, Patrick and Semb, Anne Grete and Sossalla, Samuel and Niessner, Alexander and Kaski, Juan Carlos and Dobrev, Dobromir},
title = {New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2024},
doi = {10.1093/ehjcvp/pvae013}
}
EUVIMED